Advertisement

Clinical and Translational Oncology

, Volume 20, Issue 8, pp 1072–1079 | Cite as

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

  • J. Garde-Noguera
  • P. Martin-Martorell
  • M. De Julián
  • J. Perez-Altozano
  • C. Salvador-Coloma
  • J. García-Sanchez
  • A. Insa-Molla
  • M. Martín
  • X. Mielgo-Rubio
  • S. Marin-Liebana
  • A. Blasco-Cordellat
  • S. Blasco-Molla
  • R. Gironés
  • D. Marquez-Medina
  • F. Aparisi
  • M. C. Bas Cerda
  • S. Macia-Escalante
  • A. Sánchez
  • O. Juan-Vidal
Research Article

Abstract

Background

Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need.

Patients and methods

Retrospective review of NSCLC patients treated with nivolumab was performed. Analyzed variables included age, sex, stage, performance status (PS), location of metastases, presence of tumour-related symptoms and comorbidities, number of metastasis locations, previous chemotherapy, anti-angiogenic and radiotherapy treatments, and analytical data from the standard blood count and biochemistry.

Results

A total of 175 patients were included. Median age was 61.5 years, 73.1% were men, 77.7% were ECOG-PS 0–1, and 86.7% were included with stage IV disease. Histology was non-squamous in 77.1%. Sixty-five received nivolumab in second line (37.1%). Thirty-eight patients had brain metastasis (22%), and 39 (22.3%) liver metastasis and 126 (72%) had more than one metastatic location. The ORR was 15.7% with median Progression free survival (PFS) 2.8 months and median OS 5.81 months. Stage III vs IV and time since the beginning of the previous line of treatment ≥ 6 vs < 6 months were associated with better response. PS 2, time since the previous line of treatment < 6 vs ≥ 6 months, and more than one metastatic location were independently associated with shorter OS in multivariable analysis (7.8 vs 2.7 months, 11.2 vs 4.6 months, and 9.4 vs 5.1 month). Finally, time since the previous treatment < 6 vs ≥ 6 months and more than one metastatic location were independently associated with shorter PFS in multivariable analysis (4.3 vs 2.3 months and 4.7 vs 2.3 months).

Conclusion

Poor PS, short period of time since the previous treatment, and more than one metastatic location were associated with poorer prognostic.

Keywords

Immunotherapy Nivolumab Non-small-cell lung cancer GIDO 

Notes

Funding

No funding was provided for this research work.

Compliance with ethical standards

Conflict of interest

The authors have no relevant affiliations with any organization or entity with a financial interest in with the subject matter or materials discussed in the manuscript.

Ethical approval

This study was approved by the Local Research Ethics Committees and was executed in accordance with the Declaration of Helsinki, Good Clinical Practice, and local ethical and legal requirements.

Informed consent

All enrolled patients signed informed consent.

References

  1. 1.
    International Agency for Research on Cancer (IARC). Latest world. Cancer Statistics. IARC, Lyon, France; 2013.Google Scholar
  2. 2.
    Berrino F. The EUROCARE study: strengths, limitations and perspectives of population-based, comparative survival studies. Ann Oncol. 2003;14(Suppl 5):v9–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol. 2010;5(1):29–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Cufer T, Ovcaricek T, O’Brien ME. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer. 2013;49(6):1216–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.CrossRefPubMedGoogle Scholar
  6. 6.
    Kader Y, Le Chevalier T, El-Nahas T, Sakr A. Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. Oncol Targets Ther. 2013;6:803–9.Google Scholar
  7. 7.
    Weiss JM, Stinchcombe TE. Second-line therapy for advanced NSCLC. Oncologist. 2013;18(8):947–53.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sanofi-Aventis U.S. TAXOTERE, prescribing information, (docetaxel) Injection concentrate, intravenous infusión (IV), NJ, USA. 2013; 6 Eli Lilly and Company Limited. Alimta (pemetrexed) summary of product characteristics; 2012.Google Scholar
  9. 9.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Roche Products Limited. Tarceva (erlotinib) summary of product characteristics; 2014.Google Scholar
  11. 11.
    Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicenter, double-blind, randomised phase 3 trial. Lancet. 2014;384:665–73.CrossRefPubMedGoogle Scholar
  12. 12.
    Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowsky M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-LUNG 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143–55.CrossRefPubMedGoogle Scholar
  13. 13.
    Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Eng J Med. 2015;373:1627–39.CrossRefGoogle Scholar
  14. 14.
    Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Eng J Med. 2015;373:123–35.CrossRefGoogle Scholar
  15. 15.
    Commmitee for Medicinal Products for Human Use (CHMP). European Medicines Agency Assessment report of Opdivo. EMA/246304/2016; 2016.Google Scholar
  16. 16.
    Garon EB, Rizvi NQ, Hui R, Leigh N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Eng J Med. 2015;372:2018–28.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018
corrected publication July 2018

Authors and Affiliations

  • J. Garde-Noguera
    • 1
  • P. Martin-Martorell
    • 2
  • M. De Julián
    • 3
  • J. Perez-Altozano
    • 4
  • C. Salvador-Coloma
    • 5
  • J. García-Sanchez
    • 1
  • A. Insa-Molla
    • 2
  • M. Martín
    • 6
  • X. Mielgo-Rubio
    • 7
  • S. Marin-Liebana
    • 8
  • A. Blasco-Cordellat
    • 9
  • S. Blasco-Molla
    • 10
  • R. Gironés
    • 11
  • D. Marquez-Medina
    • 12
  • F. Aparisi
    • 13
  • M. C. Bas Cerda
    • 14
  • S. Macia-Escalante
    • 15
  • A. Sánchez
    • 3
  • O. Juan-Vidal
    • 5
  1. 1.Hospital Arnau de VilanovaValenciaSpain
  2. 2.University Hospital Clínic de ValenciaValenciaSpain
  3. 3.Hospital Provincial de CastellónCastellónSpain
  4. 4.Hospital General de ElcheElcheSpain
  5. 5.Hospital Universitari I Politècnic La FeValenciaSpain
  6. 6.Hospital Dr PesetValenciaSpain
  7. 7.Hospital Universitario Fundación AlcorcónAlcorcónSpain
  8. 8.Hospital de ManisesManisesSpain
  9. 9.Hospital General Universitario de ValenciaValenciaSpain
  10. 10.Hospital de SaguntoSaguntoSpain
  11. 11.Hospital Lluis AlcanyísXátivaSpain
  12. 12.Hospital Arnau de VilanovaLleidaSpain
  13. 13.Hospital Virgen de los LiriosAlcoySpain
  14. 14.Universidad Politecnica de ValenciaValenciaSpain
  15. 15.Pivotal CROMadridSpain

Personalised recommendations